Google AI for Health Program Selects Five African Startups

By HEOR Staff Writer

October 26, 2023

AI for Health program

A New Era for African Health Startups

The 2023 cohort of the Google for Startups Growth Academy: AI for Health program has been announced. The aforementioned selection comprises a total of 30 startup companies. All originating from the regions of Europe, the Middle East, and Africa. Out of the selection, five African firms have been designated, namely mDoc and PharmaRun from Nigeria.

The selection of these firms is based on their utilization of artificial intelligence (AI) in a pioneering manner to address health-related obstacles. They have the potential to enhance healthcare by implementing artificial intelligence (AI)-based solutions. This encompasses a wide range of areas, spanning from the early diagnosis of diseases to the promotion of universal access to information.

 

The Conceptual Framework Underlying the Program

Yuval Passov, the Head of Google for entrepreneurs, articulated his perspective on the potential of African health entrepreneurs utilizing artificial intelligence (AI). The author found Africa’s pioneering attitude in the field of AI for Health to be highly motivating. The chosen startups serve as evidence of the continent’s capacity to create worldwide health solutions. Google’s objective is to align itself with these entities, providing assistance and collaboration as they endeavor to expand and distribute their innovative solutions.

The Google for businesses Growth Academy: AI for Health program aligns with Google’s goal to help businesses grow faster. This program aims to support selected African and international companies. It strives to encourage innovation and healthcare advancements. Ultimately, it seeks to create a lasting positive impact on global welfare.

Reference url

Recent Posts

orphan drug designation zoci
Orphan Drug Designation Zoci Enhances Treatment Prospects for Pulmonary Neuroendocrine Carcinomas

By João L. Carapinha

July 1, 2026

The European Medicines Agency has granted orphan drug designation for zocilurtatug pelitecan, an investigational DLL3-targeted antibody-drug conjugate, based on ...
Belgium Fast Access Medicines
Belgium Fast Access Medicines Revolutionize Treatment for IgA Nephropathy

By João L. Carapinha

July 1, 2026

Belgium Fast Access Medicines has moved from policy to practice. Authorities have granted temporary reimbursement to Atrasentan, the first therapy approved under the new Early and Equitable Fast Access procedure, offering quicker hope to patients with IgA nephropathy while anchoring the country’s...
Retracted Trial Publication
Retracted Trial Publication Undermines Support for Avacopan in AAV Treatment

By João L. Carapinha

July 1, 2026

The Retracted Trial Publication of the ADVOCATE study has eliminated the central evidence that supported approval of Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). At the request of two lead academic authors, the